Objectives:

Post-finasteride syndrome (PFS) is a little known adverse effect of 5α-reductase inhibitor (5-ARI) drugs used in benign prostatic hyperplasia (BPH) and androgenetic alopecia. Five articles on the syndrome have been published in Spain, although no review has been published. The objectives of this article are to review the world literature, including the Spanish literature. Material and

Methods:

A retrospective review on post-finasteride syndrome was performed between 2011 and 2020. The search for information in PubMed/Medline was performed using the English terms" post-finasteride, post-finasteride syndrome" and in Google with the Spanish" post-finasteride, síndrome post-finasteride". The results of the variables studied were analyzed using descriptive statistics.

Results:

A total of 64 worldwide articles on post-finasteride syndrome were found, discarding 24 (37.5%) that did not deal with the symptoms of the syndrome, and 40 articles (62.5%) by 37 authors were included for study, corresponding to 29 publications on case series (72.5%) and 11 reviews (27.5%). Of the 40 articles, 37 referred to male post-finasteride syndrome (92.5%) and 3 to female (7.5%), the number of patients studied in the review was 87,887 corresponding to 87,224 men (99.2%) and 663 women (0.7%), with the number of articles on general symptoms being 23 (57.5%), male sexual symptoms 20 (50%) and female sexual symptoms 1 (2.5%). The articles came from 14 specialties, with Dermatology 14 publications (35%), Urology-Andrology 7 (17.5%) and Pharmacology 6 (15%). The countries with the highest number of publications were the USA 15 (37.5%), Italy 7 (17.5%) and Spain 5 (12.5%).

Conclusions:

Finasteride is rarely associated with sexual and systemic adverse effects that constitute the so-called post-finasteride syndrome. There are still few studies on this syndrome in the world. This is the first review of this syndrome in Spain (AU)

RESUMEN

Introducción y

Objetivos:

El síndrome postfinasteride (SPF) es un efecto adverso poco conocido de losfármacos inhibidores de la enzima 5α reductasa (5-ARI), utilizados en hiperplasia benigna de próstata (HBP) y alopecia androgenética. En España se han publicado 5 artículos sobre el síndrome aunque ninguna revisión. Los objetivos de este artículo son realizar una revisión de la literaturamundial incluida la española. Material y

Métodos:

Se realiza una revisión retrospectiva sobre el síndrome post-finasteride entre 2011 y2020. La búsqueda de información en PubMed/Medlinese realizó mediante los términos ingleses post-finasteride, post-finasteride syndrome y en Google con los españoles post-finasteride, síndrome post-finasteride. Los resultados de las variables estudiadas se analizaron mediante estadísticas descriptivas.

Resultados:

Se encontraron un total de 64 artículosmundiales sobre síndrome post-finasteride descartándose24 (37, 5%) que no trataban sobre los síntomas del síndrome, incluyéndose para estudio 40 artículos (62, 5%) de 37 autores, correspondientes a 29 publicaciones sobre series decasos (72, 5%) y 11 revisiones (27, 5%). De los 40 artículos 37 se referían al síndrome post-finasteride masculino (92, 5%) y 3 al femenino (7, 5%), el nº de pacientes estudiados en la revisión fue 87.887 correspondientes a 87.224 hombres (99, 2%) y 663 mujeres (0, 7%), siendo el nº artículos sobre síntomas generales 23 (57, 5%), síntomas sexuales masculinos 20 (50%) y síntomas sexuales femeninos 1 (2, 5%). Los artículos procedían de 14 especialidades, destacando Dermatología 14 publicaciones (35%), Urología-Andrología 7 (17, 5%) y Farmacología 6 (15%). Los países con mayor nº de publicaciones …